Hyaluronic acid-coated niosomal sorafenib targets CD44 and suppresses NFκB signalling in oral squamous cell carcinoma
{{output}}
Objectives: Oral squamous cell carcinoma (OSCC) remains highly lethal and is driven, in part, by chronic NF-κB-mediated inflammation. Sorafenib, a multikinase inhibitor of RAF/VEGFR/PDGFR, can suppress these pathways, but its cl... ...